Wednesday, BioElectronics Corp.(BIEL.PK), a maker of disposable drug-free anti-inflammatory devices, said its ActiPatch therapy and Allay menstrual pain relief patches are safe and effective alternatives to acetaminophen, a non-prescription drug used to relieve pain and reduce fever. The stock rose nearly 22% in morning trade on OTC.
The company was reacting to the U.S. Food and Drug Administration, or FDA, panel recommendation to lower the maximum daily dosage of acetaminophen and to restrict the sale of large acetaminophen dosages such as those contained in extra strength Tylenol.
Andrew Whelan, chief executive officer of BioElectronics, said, " We welcome the FDA panel's findings that acetaminophen usage is potentially dangerous and should be restricted."
Whelan added, "We are developing significant momentum around the world in the use of both ActiPatch Therapy and the Allay Menstrual Pain Relief Patch as a safe and effective alternative to acetaminophen. We look forward delivering our proven safe and effective drug-free pain relief and healing technology to the American market as our clinical studies move toward conclusion."
The Frederick, Maryland-based BioElectronicsis the maker of patented ActiPatch Therapy, RecoveryRx Devices, HealFast Therapy and Allay family of inexpensive, disposable drug-free anti-inflammatory devices. These devices utilize embedded battery operated microchips to deliver cost effective home therapy to reduce soft tissue pain and swelling.
BIEL.PK is trading up $0.0065 or 21.31% at $0.0370 on a volume of about 87.0 million shares.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.